» Articles » PMID: 30705071

Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in -Mutant Lower Grade Gliomas

Overview
Specialty Neurology
Date 2019 Feb 2
PMID 30705071
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: ()-mutant lower grade gliomas are classified as oligodendrogliomas or diffuse astrocytomas based on 1p/19q-codeletion status. We aimed to test and validate neuroradiologists' performances in predicting the codeletion status of -mutant lower grade gliomas based on simple neuroimaging metrics.

Materials And Methods: One hundred two -mutant lower grade gliomas with preoperative MR imaging and known 1p/19q status from The Cancer Genome Atlas composed a training dataset. Two neuroradiologists in consensus analyzed the training dataset for various imaging features: tumor texture, margins, cortical infiltration, T2-FLAIR mismatch, tumor cyst, T2* susceptibility, hydrocephalus, midline shift, maximum dimension, primary lobe, necrosis, enhancement, edema, and gliomatosis. Statistical analysis of the training data produced a multivariate classification model for codeletion prediction based on a subset of MR imaging features and patient age. To validate the classification model, 2 different independent neuroradiologists analyzed a separate cohort of 106 institutional -mutant lower grade gliomas.

Results: Training dataset analysis produced a 2-step classification algorithm with 86.3% codeletion prediction accuracy, based on the following: 1) the presence of the T2-FLAIR mismatch sign, which was 100% predictive of noncodeleted lower grade gliomas, ( = 21); and 2) a logistic regression model based on texture, patient age, T2* susceptibility, primary lobe, and hydrocephalus. Independent validation of the classification algorithm rendered codeletion prediction accuracies of 81.1% and 79.2% in 2 independent readers. The metrics used in the algorithm were associated with moderate-substantial interreader agreement (κ = 0.56-0.79).

Conclusions: We have validated a classification algorithm based on simple, reproducible neuroimaging metrics and patient age that demonstrates a moderate prediction accuracy of 1p/19q-codeletion status among -mutant lower grade gliomas.

Citing Articles

Interpretable multimodal transformer for prediction of molecular subtypes and grades in adult-type diffuse gliomas.

Byeon Y, Park Y, Lee S, Park D, Shin H, Han K NPJ Digit Med. 2025; 8(1):140.

PMID: 40044878 PMC: 11883078. DOI: 10.1038/s41746-025-01530-4.


Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with -Mutant Glioma.

Nichelli L, Cadin C, Lazzari P, Mathon B, Touat M, Sanson M AJNR Am J Neuroradiol. 2024; 46(1):113-120.

PMID: 38997123 PMC: 11735446. DOI: 10.3174/ajnr.A8413.


Identification of T2W hypointense ring as a novel noninvasive indicator for glioma grade and IDH genotype.

Lu Y, Du N, Fang X, Shu W, Liu W, Xu X Cancer Imaging. 2024; 24(1):80.

PMID: 38943156 PMC: 11212435. DOI: 10.1186/s40644-024-00726-3.


Pediatric-type diffuse low-grade glioma with T2-FLAIR mismatch sign: a case report and literature review.

Hwa J, Wong A, Jung S, Wu C Childs Nerv Syst. 2024; 40(8):2271-2278.

PMID: 38884778 DOI: 10.1007/s00381-024-06487-5.


Amide proton transfer weighted and diffusion weighted imaging based radiomics classification algorithm for predicting 1p/19q co-deletion status in low grade gliomas.

Ma A, Yan X, Qu Y, Wen H, Zou X, Liu X BMC Med Imaging. 2024; 24(1):85.

PMID: 38600452 PMC: 11005152. DOI: 10.1186/s12880-024-01262-z.


References
1.
Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009; 20(1):245-54. PMC: 8094636. DOI: 10.1111/j.1750-3639.2009.00352.x. View

2.
Patel S, Poisson L, Brat D, Zhou Y, Cooper L, Snuderl M . T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res. 2017; 23(20):6078-6085. DOI: 10.1158/1078-0432.CCR-17-0560. View

3.
Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

4.
Yoon H, Ahn K, Lee S, Jang J, Choi H, Jung S . Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. Neuroradiology. 2017; 59(7):665-675. DOI: 10.1007/s00234-017-1851-x. View

5.
Kim J, Park C, Park S, Kim Y, Han J, Kim C . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2010; 82(2):224-7. DOI: 10.1136/jnnp.2009.178806. View